Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?


Journal

Mutagenesis
ISSN: 1464-3804
Titre abrégé: Mutagenesis
Pays: England
ID NLM: 8707812

Informations de publication

Date de publication:
06 03 2019
Historique:
received: 30 04 2018
revised: 02 07 2018
accepted: 28 07 2018
pmc-release: 06 03 2020
pubmed: 7 9 2018
medline: 27 4 2019
entrez: 7 9 2018
Statut: ppublish

Résumé

(Quantitative) structure-activity relationship or (Q)SAR predictions of DNA-reactive mutagenicity are important to support both the design of new chemicals and the assessment of impurities, degradants, metabolites, extractables and leachables, as well as existing chemicals. Aromatic N-oxides represent a class of compounds that are often considered alerting for mutagenicity yet the scientific rationale of this structural alert is not clear and has been questioned. Because aromatic N-oxide-containing compounds may be encountered as impurities, degradants and metabolites, it is important to accurately predict mutagenicity of this chemical class. This article analysed a series of publicly available aromatic N-oxide data in search of supporting information. The article also used a previously developed structure-activity relationship (SAR) fingerprint methodology where a series of aromatic N-oxide substructures was generated and matched against public and proprietary databases, including pharmaceutical data. An assessment of the number of mutagenic and non-mutagenic compounds matching each substructure across all sources was used to understand whether the general class or any specific subclasses appear to lead to mutagenicity. This analysis resulted in a downgrade of the general aromatic N-oxide alert. However, it was determined there were enough public and proprietary data to assign the quindioxin and related chemicals as well as benzo[c][1,2,5]oxadiazole 1-oxide subclasses as alerts. The overall results of this analysis were incorporated into Leadscope's expert-rule-based model to enhance its predictive accuracy.

Identifiants

pubmed: 30189015
pii: 5090822
doi: 10.1093/mutage/gey020
pmc: PMC6402318
doi:

Substances chimiques

Cyclic N-Oxides 0
Mutagens 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-82

Subventions

Organisme : NIEHS NIH HHS
ID : R44 ES026909
Pays : United States

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Prog Exp Tumor Res. 1961;2:158-202
pubmed: 14478105
Nat Rev Cancer. 2004 Jun;4(6):437-47
pubmed: 15170446
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D39-45
pubmed: 15608222
Altern Lab Anim. 2005 Apr;33(2):155-73
pubmed: 16180989
Chem Res Toxicol. 1992 Mar-Apr;5(2):149-53
pubmed: 1643243
Toxicol Sci. 2006 Jun;91(2):382-92
pubmed: 16547075
Mutat Res. 1991 May;257(3):229-306
pubmed: 1707500
Handb Exp Pharmacol. 2009;(192):29-60
pubmed: 19184645
Mutagenesis. 1990 Jul;5(4):307-11
pubmed: 2204783
Chem Res Toxicol. 2012 Jan 13;25(1):197-206
pubmed: 22084973
Mutat Res. 2012 Mar 18;743(1-2):10-9
pubmed: 22260876
J Clin Biochem Nutr. 2012 Jul;51(1):9-14
pubmed: 22798706
Regul Toxicol Pharmacol. 2013 Aug;66(3):326-35
pubmed: 23688841
Regul Toxicol Pharmacol. 2013 Nov;67(2):299-316
pubmed: 23988886
J Appl Genet. 2014 May;55(2):273-85
pubmed: 24615570
Curr Top Med Chem. 2014;14(11):1374-87
pubmed: 24805062
J Chem Inf Model. 2014 May 27;54(5):1500-11
pubmed: 24821140
Regul Toxicol Pharmacol. 2015 Mar;71(2):295-300
pubmed: 25545315
Curr Med Chem. 2015;22(24):2819-57
pubmed: 26087764
Regul Toxicol Pharmacol. 2015 Oct;73(1):367-77
pubmed: 26248005
Mutat Res. 1989 May;217(3):203-9
pubmed: 2654625
Food Chem Toxicol. 1989 Apr;27(4):227-32
pubmed: 2659457
Mutat Res Genet Toxicol Environ Mutagen. 2016 Jan 1;795:7-30
pubmed: 26774663
Regul Toxicol Pharmacol. 2016 Jun;77:13-24
pubmed: 26877192
Regul Toxicol Pharmacol. 2016 Jun;77:1-12
pubmed: 26879463
Front Pharmacol. 2016 Mar 21;7:64
pubmed: 27047380
Adv Exp Med Biol. 2016;856:165-187
pubmed: 27671722
Arh Hig Rada Toksikol. 2016 Sep 1;67(3):169-182
pubmed: 27749264
Mutat Res. 1988 Jan;204(1):17-115
pubmed: 3277047
Mutat Res. 1986 Sep;168(2):69-240
pubmed: 3528831
Environ Mutagen. 1987;9 Suppl 9:1-109
pubmed: 3552650
Cancer Res. 1979 Sep;39(9):3289-318
pubmed: 383284
Environ Mutagen. 1984;6 Suppl 2:1-251
pubmed: 6394312
Mutat Res. 1980 Sep;76(2):169-90
pubmed: 7005668
J Immunol Methods. 1980;36(1):55-61
pubmed: 7009752
Xenobiotica. 1980 Feb;10(2):151-7
pubmed: 7395267
Mutat Res. 1995 Oct;344(3-4):95-102
pubmed: 7491133
Proc Natl Acad Sci U S A. 1976 Mar;73(3):950-4
pubmed: 768988
Biol Pharm Bull. 1995 Feb;18(2):363-7
pubmed: 7742814
Ceska Slov Farm. 1994 Oct;43(5):240-2
pubmed: 7982008
Environ Health Perspect. 1993 Oct;101 Suppl 3:21-6
pubmed: 8143619
J Appl Toxicol. 1993 Jul-Aug;13(4):283-9
pubmed: 8376729

Auteurs

Alexander Amberg (A)

Sanofi, R&D Preclinical Safety Frankfurt, Industriepark Höchst, Frankfurt am Main, Germany.

Lennart T Anger (LT)

Sanofi, R&D Preclinical Safety Frankfurt, Industriepark Höchst, Frankfurt am Main, Germany.

Joel Bercu (J)

Gilead Sciences, Nonclinical Safety and Pathobiology, Foster City, CA, USA.

David Bower (D)

Leadscope, Inc., Columbus, OH, USA.

Kevin P Cross (KP)

Leadscope, Inc., Columbus, OH, USA.

Laura Custer (L)

Bristol-Myers Squibb, Drug Safety Evaluation, New Brunswick, NJ, USA.

James S Harvey (JS)

GlaxoSmithKline Pre-Clinical Development, Ware, Hertfordshire, UK.

Catrin Hasselgren (C)

Genentech, Inc., Safety Assessment, South San Francisco, CA, USA.

Masamitsu Honma (M)

National Institute of Health Sciences, Division of Genetics & Mutagenesis, Kamiyoga, Setagaya-ku, Tokyo, Japan.

Candice Johnson (C)

Leadscope, Inc., Columbus, OH, USA.

Robert Jolly (R)

Toxicology Division, Eli Lilly and Company, Indianapolis, IN, USA.

Michelle O Kenyon (MO)

Pfizer Worldwide Research and Development, Drug Safety, Genetic Toxicology, Groton, CT, USA.

Naomi L Kruhlak (NL)

U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA.

Penny Leavitt (P)

Bristol-Myers Squibb, Drug Safety Evaluation, New Brunswick, NJ, USA.

Donald P Quigley (DP)

Leadscope, Inc., Columbus, OH, USA.

Scott Miller (S)

Leadscope, Inc., Columbus, OH, USA.

David Snodin (D)

Xiphora Biopharma Consulting, Bristol, UK.

Lidiya Stavitskaya (L)

U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA.

Andrew Teasdale (A)

AstraZeneca, Pharmaceutical Technology and Development, Macclesfield, Cheshire, UK.

Alejandra Trejo-Martin (A)

AstraZeneca, Pharmaceutical Technology and Development, Macclesfield, Cheshire, UK.

Angela T White (AT)

GlaxoSmithKline Pre-Clinical Development, Ware, Hertfordshire, UK.

Joerg Wichard (J)

Bayer AG, Pharmaceuticals Division, Investigational Toxicology, Muellerstr, Berlin, Germany.

Glenn J Myatt (GJ)

Leadscope, Inc., Columbus, OH, USA.

Articles similaires

Alzheimer Disease Humans Regression Analysis Quantitative Structure-Activity Relationship Drug Design
DNA Glycosylases Nucleosomes Humans 8-Hydroxy-2'-Deoxyguanosine DNA Repair
Humans Induced Pluripotent Stem Cells Schizophrenia Neural Stem Cells DNA Damage

Novel

Febe Ferro, C Roland Wolf, Christopher Henstridge et al.
1.00
Amyotrophic Lateral Sclerosis Animals Mice DNA-Binding Proteins Disease Models, Animal

Classifications MeSH